Abbott India Ltd (Abbott India), a subsidiary of Abbott Laboratories, focuses on the development and distribution of a broad range of science-led nutritional products, diagnostic solutions, branded generic medicines, and diabetes and vascular devices. The company supports multiple segments, including women's health, gastroenterology, cardiology, metabolic conditions, and primary care. It provides a wide set of products and services across these areas. Its portfolio comprises more than 600 offerings designed to enhance health and well-being for people across every stage of life. These offerings cover nutrition, diagnostics, medical care, and pharmaceutical treatment. The company’s products address diverse therapeutic categories, including anti-infectives, cardio-diabeto, GI & Hepto, hormones, neuro-psychiatry, pain management, respiratory, women's health, hepatic, neuroscience, metabolics, vaccine, gennext, and consumer care. It also provides gastroenterology products for conditions affecting the gastrointestinal tract, and CNS products for illnesses such as vertigo, migraine, depression, and insomnia. Within women's health, Abbott India concentrates on managing chronic metabolic disorders such as hypothyroidism. The company functions through a single business segment: Pharmaceuticals. Key brands in this segment include Cremaffin (laxative), Cremaffin Plus (laxative), Duphaston (women’s health hormone), Duphalac (laxative), Udiliv (hepatic protective), Creon (digestive enzymes), Heptral (alcoholic liver disease), Rowasa (inflammatory bowel syndrome), Conifex (constipation), Cremapeg (irritable bowel syndrome), and Dirifa (diarrhoea). The speciality care division includes a range of products for the management of CNS and metabolic disorders. The CNS portfolio includes Vertin and Prothiaden, while metabolics includes products such as Thyronorm. Leading brands in speciality care include Prothiaden (antidepressant), Thyronorm (thyroid preparation), Vertin (anti-vertigo), and Inderal (migraine prophylaxis). The GenNext division provides multi-speciality medicines focused on pain management and vitamins. Major brands include Brufen (painkiller), Duvadilan (peripheral vasodilator), Zolfresh (sleep management), Arachitol (Vitamin D nano preparations), and Digecaine (antacid anaesthetic). Abbott India’s vaccine portfolio includes Influvac for influenza, Enteroshield for typhoid, and Rotasure for diarrhoea. The consumer care division includes the OTC antacid category, offering all variants of the Digene (antacid–antiflatulent) brand. It operates a manufacturing facility in Goa for the development of multiple new pharmaceutical formulations. It distributes products through independent distributors mainly across India. The company collaborates with third-party manufacturers in India and licenses products in specific therapeutic areas such as gastroenterology, metabolism, CNS, and women’s health. It launched five new products during FY2026. The company markets its products in India, Sri Lanka, Nepal, the Maldives, and Bhutan.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Abbott India constantly assesses and understands customer needs to identify gaps and unmet needs. The company develops new medicines specifically tailored to meet these challenges, promoting innovation and improving patient outcomes. The company introduced five new products in FY2026 across different therapeutic areas. The company also engages with healthcare professionals and runs campaigns to improve patient health outcomes. In addition, Abbott India operates health clinics offering diagnosis and awareness across a range of symptomatic and asymptomatic conditions in India. The company also conducted 21 new clinical studies and published 35 medical publications. In FY2026, the company spent INR6.2 million, which, as a percentage of revenue, stood at 0.08%.